Ibrexafungerp citrate is a triterpenoid antifungal. Similarly to echinocandins, it inhibits the synthesis of 1,3-β-d-glucan. However, it binds to a different site on the enzyme than echinocandins, resulting in limited cross-resistance. Ibrexafungerp exerts concentration-dependent fungicidal activity against Candida species and retains in vitro activity against most fluconazole-resistant strains.
Cat.No
DC44113
Name
Ibrexafungerp citrate
Chemical Properties
CAS
1965291-08-0
Formula
C50H75N5O11
MW
922.157414674759
Storage
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
References
1: Sucher AJ, Thai A, Tran C, Mantena N, Noronha A, Chahine EB. Ibrexafungerp: A new triterpenoid antifungal. Am J Health Syst Pharm. 2022 Sep 9:zxac256. doi: 10.1093/ajhp/zxac256. Epub ahead of print. PMID: 36083109.
2: Grant LM, Orenstein R. Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp. J Investig Med High Impact Case Rep. 2022 Jan- Dec;10:23247096221123144. doi: 10.1177/23247096221123144. PMID: 36059275; PMCID: PMC9445446.
3: Díaz-García J, Gómez A, Machado M, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, Gómez-García De La Pedrosa E, González-Romo F, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Muñoz-Algarra M, Durán-Valle MT, Sánchez-García A, Muñoz P, Escribano P, Guinea J; CANDIMAD Study Group. Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris. J Antimicrob Chemother. 2022 Aug 29:dkac288. doi: 10.1093/jac/dkac288. Epub ahead of print. PMID: 36031723.
4: Wiederhold NP. Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents. J Fungi (Basel). 2022 Aug 16;8(8):857. doi: 10.3390/jof8080857. PMID: 36012845; PMCID: PMC9410397.
5: Oteseconazole (Vivjoa) for recurrent vulvovaginal candidiasis. Med Lett Drugs Ther. 2022 Aug 8;64(1656):124-126. PMID: 35921077.
6: Díaz-García J, Gómez A, Alcalá L, Reigadas E, Sánchez-Carrillo C, Pérez-Ayala A, Gómez-García de la Pedrosa E, González-Romo F, Merino-Amador P, Cuétara MS, García-Esteban C, Quiles-Melero I, Zurita ND, Muñoz-Algarra M, Sánchez-Romero I, Durán-Valle MT, Sánchez-García A, Alcoceba E, Muñoz P, Escribano P, Guinea J; CANDIMAD study group. Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0071022. doi: 10.1128/aac.00710-22. Epub 2022 Jul 19. PMID: 35852369; PMCID: PMC9380585.
7: Logan A, Wolfe A, Williamson JC. Antifungal Resistance and the Role of New Therapeutic Agents. Curr Infect Dis Rep. 2022;24(9):105-116. doi: 10.1007/s11908-022-00782-5. Epub 2022 Jul 5. PMID: 35812838; PMCID: PMC9255453.
8: Hoenigl M, Sprute R, Arastehfar A, Perfect JR, Lass-Flörl C, Bellmann R, Prattes J, Thompson GR 3rd, Wiederhold NP, Al Obaidi MM, Willinger B, Arendrup MC, Koehler P, Oliverio M, Egger M, Schwartz IS, Cornely OA, Pappas PG, Krause R. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022 Aug;31(8):795-812. doi: 10.1080/13543784.2022.2086120. Epub 2022 Jun 15. PMID: 35657026; PMCID: PMC9339492.
9: Quindós G, Miranda-Cadena K, San-Millán R, Borroto-Esoda K, Cantón E, Linares-Sicilia MJ, Hamprecht A, Montesinos I, Tortorano AM, Prigitano A, Vidal- García M, Marcos-Arias C, Guridi A, Sanchez-Reus F, Machuca-Bárcena J, Rodríguez-Iglesias MA, Martín-Mazuelos E, Castro-Méndez C, López-Soria L, Ruiz- Gaitán A, Fernandez-Rivero M, Lorenzo D, Capilla J, Rezusta A, Pemán J, Guarro J, Pereira J, Pais C, Romeo O, Ezpeleta G, Jauregizar N, Angulo D, Eraso E. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Front Cell Infect Microbiol. 2022 May 16;12:906563. doi: 10.3389/fcimb.2022.906563. PMID: 35651755; PMCID: PMC9149255.
10: Daraskevicius J, Petraitis V, Davainis L, Zucenka A. The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies. J Fungi (Basel). 2022 Apr 23;8(5):440. doi: 10.3390/jof8050440. PMID: 35628696; PMCID: PMC9144376.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
